ISRGHealthcare · Medical Instruments & SuppliesThe 34 Wall Street analysts covering Intuitive Surgical, Inc. hold a median 12-month price target of $488 — +1.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 86 of 100 as at 3 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Intuitive Surgical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (99): Analysts have, on balance, been raising their forecasts.
Momentum (45): The shares have been drifting down relative to others.
Size (2): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on ISRG, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +1.2% from it.
Of the 20 most recent actions, 4 moved their price target up and 5 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 21 Oct 2026 | Baird | Maintains | Outperform | $513 → $550 |
| 21 Oct 2026 | Barclays | Maintains | Overweight | $485 → $500 |
| 21 Oct 2026 | BTIG | Reiterates | Buy | $454 |
| 21 Oct 2026 | Evercore ISI Group | Maintains | In-Line | $400 → $385 |
| 21 Oct 2026 | JP Morgan | Maintains | Overweight | $450 → $475 |
| 21 Oct 2026 | Leerink Partners | Maintains | Outperform | $473 → $503 |
| 21 Oct 2026 | Mizuho | Maintains | Neutral | $415 → $400 |
| 21 Oct 2026 | RBC Capital | Maintains | Outperform | $575 → $550 |
| 21 Oct 2026 | TD Cowen | Reiterates | Buy | $485 |
| 21 Oct 2026 | Wells Fargo | Maintains | Overweight | $487 → $486 |
| 12 Oct 2026 | BTIG | Maintains | Buy | $469 → $454 |
| 12 Oct 2026 | BTIG | Maintains | Buy | — |
| 7 Oct 2026 | Barclays | Initiates | Overweight | $485 |
| 7 Oct 2026 | Barclays | Initiates | Overweight | — |
| 8 Sept 2026 | BTIG | Reiterates | Buy | — |
| 8 Sept 2026 | BTIG | Reiterates | Buy | $469 |
| 12 Aug 2026 | Oppenheimer | Upgrade | Outperform | $500 |
| 12 Aug 2026 | Oppenheimer | Upgrade | Outperform | — |
| 30 July 2026 | HSBC | Downgrade | Hold | $931 |
| 30 July 2026 | HSBC | Downgrade | Hold | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ISRG appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Intuitive Surgical, Inc. returned −10.5% against +12.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 13% of US stocks
Cheaper than 11% of US stocks
Cheaper than 9% of US stocks
Cheaper than 7% of US stocks
Higher than 71% of US stocks
Higher than 18% of US stocks
Higher than 81% of US stocks
Higher than 88% of US stocks
Higher than 86% of US stocks
Higher than 79% of US stocks
Higher than 95% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Intuitive Surgical, Inc. has a market value of $155.7B and an enterprise value of $147.5B.
Revenue in the twelve months to 30 June 2026: $11.0B. The latest quarter grew 21.7% year on year.
Net income over the same four quarters: $3.2B, a 28.6% net margin.
Diluted earnings per share, trailing twelve months: $8.73.
Free cash flow in the twelve months to 30 June 2026: $3.2B, after $483.8M of capital spending.
Intuitive Surgical, Inc. spent $3.6B on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 53.4×; forward P/E: 35.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Intuitive Surgical, Inc. employs 17,021 people — $648K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Intuitive Surgical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research says its Style Scores help investors find top-rated stocks based on their investing style, and presents Intuitive Surgical as a strong momentum stock.
Why it matters — ISRG watchers may note the article’s positive momentum framing and its reference to Zacks’ Style Scores as the basis for the discussion.
Intuitive announced that Aaron Martin, President of Insurance at Humana, will join its board of directors effective January 1, 2027.
Why it matters — The appointment adds a new director to Intuitive’s board, a governance update relevant to company watchers.
The headline reports that Intuitive Surgical stock fell despite a 22% revenue jump. The excerpt highlights the company’s large da Vinci installed base and says parts and services are its biggest revenue source by a wide margin.
Why it matters — The revenue mix and installed base provide context for interpreting the reported revenue growth and the stock’s decline.
Zacks Investment Research says Intuitive Surgical’s surging robotic surgery demand and stronger earnings momentum make it a better buy than Boston Scientific, despite a valuation premium.
Why it matters — The comparison highlights demand and earnings momentum as reasons an ISRG watcher may view the company favorably relative to Boston Scientific.
Intuitive Surgical reported third-quarter 2026 revenue of just over $3 billion, up 22% year over year, while total da Vinci and Ion procedures grew 15%. The excerpt attributes revenue growth exceeding procedure growth to its installed base, system placements and adoption of newer technologies.
Why it matters — The gap between revenue and procedure growth highlights how installed-base expansion, placements and newer technology adoption contributed to ISRG's reported sales growth.
The 34 Wall Street analysts covering Intuitive Surgical, Inc. have a median 12-month price target of $488, with estimates ranging from $324 to $685. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 34 analysts covering Intuitive Surgical, Inc., 26 rate it a Buy, 6 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Intuitive Surgical, Inc. 86 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Nov 2026, Intuitive Surgical, Inc. ranks 86 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (99 of 100).
No one can know that. What the data says: the median 12-month target from 34 analysts implies +1.2% from the last close, and Ticker Nerd's factor model ranks Intuitive Surgical, Inc. 86 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Intuitive Surgical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ISRG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $324 to $685 over the next 12 months.
Intuitive Surgical, Inc. returned -10.5% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Intuitive Surgical Inc. is a medical technology company focused on robotic-assisted and minimally invasive care.
The most recent item we track (Zacks Investment Research, 4 Nov 2026): "Here's Why Intuitive Surgical, Inc. (ISRG) is a Strong Momentum Stock". Zacks Investment Research says its Style Scores help investors find top-rated stocks based on their investing style, and presents Intuitive Surgical as a strong momentum stock.
Intuitive Surgical Inc. is a medical technology company focused on robotic-assisted and minimally invasive care. Intuitive Surgical develops, manufactures, and markets the da Vinci surgical systems, which are used by surgeons to perform procedures with enhanced precision through a minimally invasive approach. The company also offers the Ion endoluminal system, extending its platform into diagnostic endoluminal procedures and lung biopsy applications. In addition to its core systems, Intuitive Surgical supports hospitals and healthcare providers with instruments, accessories, and services that help integrate robotic surgery into clinical workflows. Its products serve a broad range of specialties, including general surgery, urology, gynecology, thoracic surgery, and diagnostic care. Headquartered in Sunnyvale, California, Intuitive Surgical plays a significant role in the global healthcare equipment market by advancing the adoption of robotic systems in modern surgical and diagnostic settings.
CEO Mr. David J. Rosa · 17,021 employees · United States · https://www.intuitive.com
